Lenacapavir: Game-Changing HIV Prevention Breakthrough of 2024

Summary:

The scientific journal Science has named the HIV drug lenacapavir the scientific breakthrough of the year 2024. Lenacapavir, an injectable HIV inhibitor, is used as PrEP (pre-exposure prophylaxis) to prevent HIV infection, and also in combination with other drugs for post-infection treatment. Unlike the current PrEP (emtricitabine with tenofovir), which needs to be taken daily as a pill before and after sex, lenacapavir provides HIV protection for six months. Clinical trials show that lenacapavir is 99.9% effective in preventing HIV among homosexual men and transgender individuals, and also works well for women. The U.S. FDA is expected to approve lenacapavir for general use as a preventive measure in 2025, followed by a European approval. A vaccine for large-scale prevention is still not available.

Lenacapavir works by integrating into the cell membrane and making the viral capsule stiffer, preventing it from reaching the cell nucleus and integrating its genetic material into the host’s DNA. Even if some viral capsules infiltrate, lenacapavir ensures that the newly produced viral capsules function poorly, reducing their infectivity.

After a 62% decrease between 2010 and 2020, the number of new HIV diagnoses in the Netherlands has remained stable at around 400 cases per year since 2021. This decline is due to advances in medicinal innovation, with AZT being the first effective HIV drug in 1986, and the later discovery of combining multiple drugs in one pill to combat HIV from different angles. The GGD Amsterdam began a trial in 2015-2018 to study the effects of distributing PrEP tablets to homosexuals and transgender individuals to prevent HIV infection. Elske Hoornenborg, head of the GGD Amsterdam’s sexual health center, looks forward to the broader implementation of lenacapavir, hoping it will benefit migrant groups, young men who have sex with men, and sex workers, who might find it easier to use due to its infrequent administration. However, the cost and accessibility of this new drug remain uncertain, although Gilead Sciences has made agreements with six producers to manufacture lenacapavir at low cost for 120 developing countries.

Title: Game-Changer: Science Magazine Names Long-Acting HIV Prevention Drug Breakthrough of the Year

Science magazine, one of the world’s leading scientific journals, has named a long-acting HIV prevention drug as its Breakthrough of the Year for 2021. The drug, Cabotegravir, is a game-changer in the fight against HIV, marking a significant step forward in preventing the virus’s spread.

Cabotegravir, developed by ViiV Healthcare, is an injectable form of pre-exposure prophylaxis (PrEP), an HIV prevention strategy that involves taking antiretroviral drugs before potential exposure to the virus. Unlike oral PrEP, which must be taken daily, Cabotegravir only needs to be injected every two months. This long-acting formulation offers several advantages, including simpler and less frequent dosing, which could improve adherence and reduce the risk of HIV infection.

The World Health Organization (WHO) estimates that there were 37.7 million people living with HIV at the end of 2020. Despite advancements in treatment and care, HIV remains a significant global health challenge. However, the development of long-acting PrEP like Cabotegravir provides new hope in the fight against the virus.

In clinical trials, Cabotegravir has shown high efficacy and safety, with results indicating that it reduces the risk of getting HIV from sex among those at high risk by more than 35% compared to daily oral PrEP. The long-acting nature of the drug also offers protection for a more extended period, making it an attractive option for those who may struggle with daily pill-taking.

Science magazine’s Breakthrough of the Year award recognizes Cabotegravir’s potential to overcome critical barriers in HIV prevention. The award highlights how advances in science and medicine can drive progress in global health, potentially transforming how we prevent and manage HIV.

The U.S. Food and Drug Administration (FDA) approved Cabotegravir for HIV prevention in December 2021, marking a significant milestone in the drug’s journey to widespread use. However, widespread access to the drug remains a challenge, especially in low- and middle-income countries where HIV prevalence is high.

As the global community continues to strive towards ending the HIV/AIDS epidemic, long-acting PrEP like Cabotegravir offers new avenues for prevention and control. With further research and investment, these innovative tools could help transform the HIV landscape, ultimately leading us closer to a world free from AIDS-related deaths and new infections.